^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CXCL13 expression

    i
    Other names: CXCL13, ANGIE, ANGIE2, BCA-1, BLC, BLR1L, SCYB13, Chemokine (C-X-C motif) ligand 13
    Entrez ID:
    10563
    Related biomarkers:
    Expression
    Mutation
    Others
    9d
    Single-cell transcriptomic analyses reveal distinct immune cell contributions to epithelial barrier dysfunction in checkpoint inhibitor colitis. (PubMed, Nat Med)
    Luminal epithelial cells in patients with irColitis expressed PCSK9, PD-L1 and interferon-induced signatures associated with apoptosis, increased cell turnover and malabsorption. Together, these data suggest roles for circulating T cells and epithelial-immune crosstalk critical to PD-1/CTLA-4-dependent tolerance and barrier function and identify potential therapeutic targets for irColitis.
    Journal • Checkpoint inhibition • Immune cell
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ITGAE (Integrin Subunit Alpha E) • ITGB2 (Integrin Subunit Beta 2)
    |
    PD-L1 expression • CXCL13 expression • PCSK9 expression
    9d
    Transcriptome deconvolution reveals absence of cancer cell expression signature in immune checkpoint blockade response. (PubMed, Cancer Res Commun)
    Strikingly, PD-L1 expression in stromal cells, but not cancer cells, is correlated with ICB response across cancer types. Furthermore, the unbiased transcriptome-wide analysis failed to identify cancer-cell intrinsic expression signatures of ICB response conserved across tumor types, suggesting that cancer cells lack tissue-agnostic transcriptomic features of ICB response.
    Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Checkpoint block
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    PD-L1 expression • CXCL13 expression
    16d
    T-cell expression of CXCL13 is associated with immunotherapy response in a sex-dependent manner in patients with lung cancer. (PubMed, Cancer Immunol Res)
    Furthermore, increased expression of CXCL13 was associated with response to PD-1-targeting immunotherapy in female but not male patients. These findings suggest that there are sex-based differences in T-cell function required for response to anti-PD-1 therapy in lung cancer that may need to be considered during patient treatment decisions.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    1m
    Unlocking PD-1 antibody resistance: The MUC1 DNA vaccine augments CD8+ T cell infiltration and attenuates tumour suppression. (PubMed, Scand J Immunol)
    In summary, our findings advocate for integrated therapy as a potent mechanism for surmounting PD1 antibody resistance, capitalizing on improved T-cell functionality and infiltration. This investigation affords critical perspectives on enhancing anti-tumour immunity through the application of innovative therapeutic strategies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MUC1 (Mucin 1) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • GZMB (Granzyme B)
    |
    CXCL13 expression
    1m
    Unraveling the Heterogeneity of CD8+ T-Cell Subsets in Liver Cirrhosis: Implications for Disease Progression. (PubMed, Gut Liver)
    : In summary, this comprehensive study defines specialized CD8+ T-cell subpopulations in cirrhosis, with CXCL13+ Tex cells displaying an exhausted phenotype associated with immune dysregulation and advanced disease. Key genes and pathways regulating these cells present potential therapeutic targets.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • TNFRSF9 (TNF Receptor Superfamily Member 9) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    LAG3 expression • CXCL13 expression
    2ms
    Single cell deciphering of progression trajectories of the tumor ecosystem in head and neck cancer. (PubMed, Nat Commun)
    Finally, we delineate the distinct features of malignant epithelial cells in primary and recurrent tumors, providing a theoretical foundation for the precise selection of targeted therapy for tumors at different stages. In summary, the current study offers a comprehensive landscape and deep insight into epithelial and microenvironmental reprogramming throughout initiation, progression, lymph node metastasis and recurrence of head and neck squamous cell carcinoma.
    Journal
    |
    CD8 (cluster of differentiation 8) • SPP1 (Secreted Phosphoprotein 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • POSTN (Periostin)
    |
    CXCL13 expression • CXCL13 overexpression
    2ms
    Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. (PubMed, NPJ Precis Oncol)
    Furthermore, when applied to biopsied treatment-naïve tumor samples, higher TLS ratios predicted a positive immunotherapy response across multiple cohorts, including specific therapies for esophageal squamous cell carcinoma, non-small cell lung cancer, and stomach adenocarcinoma. In conclusion, our deep learning-based approach offers an automated and reproducible method for TLS segmentation and quantification, highlighting its potential in predicting immunotherapy response and informing cancer prognosis.
    Journal • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    2ms
    Sonic hedgehog restrains the ubiquitin-dependent degradation of SP1 to inhibit neuronal/glial senescence associated phenotypes in chemotherapy-induced peripheral neuropathy via the TRIM25-CXCL13 axis. (PubMed, J Adv Res)
    These findings provide evidence for the role of PTX-induced senescence in DRG sensory neurons and Schwann cells, suggesting that Shh could be a potential therapeutic target for CIPN.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    CXCL13 expression
    |
    paclitaxel
    2ms
    Transcriptome analysis reveals the clinical significance of CXCL13 in Pan-Gyn tumors. (PubMed, J Cancer Res Clin Oncol)
    Overall, this study provides comprehensive insights into the commonalities and differences of CXCL13 in Pan-Gyn, potentially opening new avenues for personalized treatment.
    Journal • BRCA Biomarker
    |
    BRCA (Breast cancer early onset) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    2ms
    An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. (PubMed, Cell Rep Med)
    The anti-tumoral effect of the Tfh-dependent TLS is mediated through interleukin-21 (IL-21)-IL-21 receptor signaling. Our study establishes an anti-tumoral role of the Tfh-dependent TLS in the development of LUAD.
    Journal • Immune cell
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • IL21 (Interleukin 21)
    |
    CXCL13 expression
    3ms
    Stem-like progenitor and terminally differentiated TFH-like CD4+ T cell exhaustion in the tumor microenvironment. (PubMed, Cell Rep)
    TFH-like cytotoxic CD4+ T cells have high LAG-3/BLIMP1 and low TCF1 expression without self-renewal ability, whereas non-cytotoxic TFH cells express low LAG-3/BLIMP1 and high TCF1 with self-renewal ability, closely resembling the relationship between terminally differentiated and stem-like progenitor exhaustion in CD8+ T cells, respectively. Our findings provide deep insights into TFH-like CD4+ T cell exhaustion with helper progenitor and cytotoxic differentiated functions, mediating anti-tumor immunity orchestrally with CD8+ T cells.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • PRDM1 (PR/SET Domain 1)
    |
    LAG3 expression • CXCL13 expression
    4ms
    CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma. (PubMed, Int J Immunopathol Pharmacol)
    Finally, CXCL13 significantly increased the response to cancer immunotherapy. CXCL13 may function as a potential biomarker for predicting prognosis and immunotherapy response and associate with TLSs in HNSCC.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CD8 expression • CXCL13 expression
    5ms
    Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China. (PubMed, Front Immunol)
    In NSCLC tissues, higher expression of CXCL13 was associated with better clinical outcomes (P=0.032) and higher expression of CD8 was associated with prolonged survival (P=0.022). Low baseline NLR in peripheral blood and high expression of CD8 in tissues are associated with longer PFS and may have a potential predictive value for patients with stage III-IV NSCLC using ICIs.
    Retrospective data • Journal • Checkpoint inhibition • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    PD-L1 expression • CXCL13 expression • PD-L1-L
    5ms
    Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma. (PubMed, J Clin Oncol)
    We identified the interaction of CXCR5+ HRS cells with ligand-expressing CXCL13+ macrophages as a prominent crosstalk axis in relapsed CHL. Harnessing this TME biology, we developed a novel prognostic model applicable to r/r CHL biopsies, RHL4S, opening new avenues for spatial biomarker development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CD68 (CD68 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CXCL13 expression
    5ms
    Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and in vitro experiments. (PubMed, Front Immunol)
    Furthermore, prognostic analysis revealed unfavorable outcomes of patients with a high proportion of CD4 CTLs in OSCC lesions. Our study provides a dynamic landscape of lymphocytes and demonstrates a systemic investigation of CD4 CTL effects infiltrating into OSCC lesions, which may share some pathogenesis reported in severe T and B cell-activated diseases such as autoimmune and infectious diseases.
    Preclinical • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CD27 (CD27 Molecule)
    |
    CXCL13 expression
    6ms
    Spatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma (ASH 2023)
    Our study revealed the spatial organization of the tumor microenvironment of AITL. We envision that combining multiplexed immunofluorescence and Spatial CITE-seq will further our understanding of the AITL tumor environment and could lead to the discovery of novel clinical targets.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • DNMT3A (DNA methyltransferase 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • TET2 (Tet Methylcytosine Dioxygenase 2) • CD34 (CD34 molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ICOS (Inducible T Cell Costimulator) • CD68 (CD68 Molecule) • GZMB (Granzyme B) • MME (Membrane Metalloendopeptidase) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    CXCL13 expression
    6ms
    Molecular markers that predict response to combined radiotherapy and immunotherapy in patients with lung adenocarcinoma: a bioinformatics analysis. (PubMed, Transl Cancer Res)
    Further analysis revealed that TLR8 and CCR5 expression increased responsiveness to immunotherapy by promoting M0 macrophage and memory B cell infiltration of LUAD tissues. In patients with LUAD, TLR8 and CCR5 expression are potential markers of a favorable response to combined immunotherapy and RT.
    Journal • IO biomarker
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCR5 (C-C Motif Chemokine Receptor 5) • TLR8 (Toll Like Receptor 8)
    |
    CD19 expression • CCR5 expression • PTPRC expression • CXCL13 expression
    6ms
    CXCL13 promotes thermogenesis in mice via recruitment of M2 macrophage and inhibition of inflammation in brown adipose tissue. (PubMed, Front Immunol)
    Mechanically, CXCL13 could promote thermogenesis via recruiting M2 macrophages in the BAT and, in the meantime, inhibiting pro-inflammatory factor TNFα level. This study revealed the novel role of adipose chemokine CXCL13 in the regulation of BAT activity and thermogenesis.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    6ms
    CT-based radiomics prediction of CXCL13 expression in ovarian cancer. (PubMed, Med Phys)
    CXCL13 is a candidate predictive biomarker for OC and correlates with the degree of plasma cell and eosinophil infiltration.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CXCL13 expression
    7ms
    SINGLE CELL DISSECTION OF HUMAN CHECKPOINT INHIBITOR AND AUTOIMMUNE HEPATITIS REVEALS INSIGHTS INTO LIVER IMMUNE TOLERANCE (AASLD 2023)
    In defining the cellular and transcriptional programs that are altered in irHepatitis and AIH, we have identified novel pathways that could be therapeutically targeted to treat liver inflammation and have determined how PD-1 and CTLA-4 signaling may contribute to immune tolerance in the liver.
    Checkpoint inhibition
    |
    CD8 (cluster of differentiation 8) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    8ms
    Dynamic single-cell mapping unveils Epstein‒Barr virus-imprinted T-cell exhaustion and on-treatment response. (PubMed, Signal Transduct Target Ther)
    In accordance, anti-LAG-3 therapy could effectively reduce tumour burden in refractory EBV (+) GC patients. Our results delineate a distinct implication of EBV-imprinted on-treatment T-cell immunity in GC, which could be leveraged to optimize the rational design of precision immunotherapy.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    9ms
    Location of CD39 T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer. (PubMed, J Immunother Cancer)
    Knowledge of patterns of distribution and location are required to understand the prognostic impact of CD39 T cell populations in NSCLC. This study provides an improved understanding of spatial and functional characteristics of CD39 T cells and their significance to patient outcome.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • EPCAM (Epithelial cell adhesion molecule) • NT5E (5'-Nucleotidase Ecto) • ITGAE (Integrin Subunit Alpha E) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    CD73 expression • CXCL13 expression • EPCAM expression • ENTPD1 expression
    9ms
    Construction of enhanced CT radiomics model for noninvasive prediction of CXCL13's expression and immune infiltrates in bladder cancer based on logistic regression and support vector machine algorithm. (PubMed, Asian J Surg)
    No abstract available
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    10ms
    Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta. (PubMed, Front Immunol)
    CAF provide TGF-β during T cell activation and reduce availability of IL-2 both directly (by reducing the capacity for IL-2 production) and indirectly, by expanding a population of activated Treg. Inhibition of TGF-β signalling prevented both CAF-driven upregulation of CXCL13 and Treg expansion. Promoting CXCL13 production represents a newly described immune-regulatory function of CAF with the potential to shape the immune infiltrate of the tumour microenvironment both by altering the effector-function of tumour infiltrating T-cells and their capacity to attract B cells and promote TLS formation.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TGFB1 (Transforming Growth Factor Beta 1) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    |
    CXCL13 expression
    10ms
    Expression of lymphoid structure-associated cytokine/chemokine gene transcripts in tumor and protein in serum are prognostic of melanoma patient outcomes. (PubMed, Front Immunol)
    Patients exhibiting high coordinate expression of APRIL/CXCL10/CXCL13 transcripts in their tumors displayed superior OS. Further investigation of TLS-kine expression profiles related to clinical outcomes in larger cohort studies is warranted.
    Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • TNFSF13 (TNF Superfamily Member 13)
    |
    CXCL10 expression • CXCL13 expression
    11ms
    Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation. (PubMed, Nat Cancer)
    In this subgroup, high pTRT cell abundance was comparable to that in primary lung cancer, whereas all other brain tumors had low levels, similar to primary breast cancer. These findings indicate that T cell-mediated tumor reactivity can occur in certain brain metastases and may inform stratification for treatment with immunotherapy.
    Journal • Metastases
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    CXCL13 expression • ENTPD1 expression
    11ms
    Tfl deletion induces extraordinary Cxcl13 secretion and cachexia in VavP-Bcl2 transgenic mice. (PubMed, Front Immunol)
    These data suggest Tfl regulates Cxcl13 in B220IgM cells in the bone marrow, and a very high concentration of serum Cxcl13 arising from these cells may contribute to early death in lymphoma-bearing mice. Since several reports have suggested the association of CXCL13 expression with lymphoma, these findings provide new insights into cytokine regulation via TFL in lymphoma.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    BCL2 overexpression • BCL2 expression • CXCL13 expression
    1year
    Transcription factor Fli-1 impacts the expression of CXCL13 and regulates immune cell infiltration into the kidney in MRL/lpr mouse. (PubMed, Lupus Sci Med)
    Fli-1 regulates renal Sox4 mRNA expression and infiltration of CXCR5-positive cells as well as CXCL13/CD11b double-positive immune cells into the kidney, which affects CXCL13 expression and lupus-like nephritis.
    Preclinical • Journal • Immune cell
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • ITGAM (Integrin, alpha M) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SOX4 (SRY-Box Transcription Factor 4)
    |
    CXCL13 expression
    1year
    Predictive models of recurrence from transcriptomic signatures of the tumor microenvironment and cell cycle in stage III colon cancer from PETACC-8 and IDEA France trials. (ASCO 2023)
    Using transcriptomic data of patients with stage III CC from 2 large-scale adjuvant trials, two predictive models based on signatures of the TME and the cell cycle, provide important information in addition to known prognostic factors for patient stratification on risk of recurrence. Beyond T and N stage, for the decision of adjuvant chemotherapy in stage III CC, the combination of these different variables could be exploited in the future for personalized care (de-escalation, intensification). >
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    |
    Oncotype DX® Colon Recurrence Score test
    1year
    Tertiary lymphoid structures and chemokine landscape in virus-positive and virus-negative Merkel cell carcinoma (EADO 2023)
    TLSs can be a useful prognostic marker in MCPyV-negative MCC, which is ultraviolet-induced and has many genetic mutations and neoantigens. On the other hand, MCPyV-positive MCCs seem to have a different mechanism of tumor immune activation. Elucidation of this mechanism will help us understand tumor immunity in MCC, which is strange compared to other tumors.
    IO biomarker
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CCL5 (Chemokine (C-C motif) ligand 5) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCR7 (Chemokine (C-C motif) receptor 7) • CCR2 (C-C Motif Chemokine Receptor 2) • CX3CR1 (C-X3-C Motif Chemokine Receptor 1)
    |
    CXCL13 expression
    1year
    The synergized diagnostic value of VTQ with chemokine CXCL13 in lung tumors. (PubMed, Front Oncol)
    Additionally, the findings suggest that elevated relative expression of CXCL13 in cases of malignant pleural effusion caused by non-small cell lung cancer may indicate a poor prognosis. This provides promising potential for using CXCL13 as a screening tool and prognostic indicator for patients with advanced lung cancer complicated by malignant pleural effusion.
    Journal
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    1year
    B cell-dependent subtypes and treatment-based immune correlates to survival in stage 3 and 4 lung adenocarcinomas. (PubMed, FASEB Bioadv)
    Notably and unexpectedly pre-treatment percentages of intratumoral B cells are associated with PFS in patients who receive surgery, chemotherapy, or radiation. Further studies to confirm these findings would allow for more effective patient selection for both ICI and non-ICI treatments.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    PD-1 expression • CXCL13 expression
    1year
    Single-cell Profiling of Tumor Immune Microenvironment Reveals Immune Irresponsiveness in Gastric Signet-ring Cell Carcinoma. (PubMed, Gastroenterology)
    Our study provides a comprehensive molecular portrait of immune cell compositions and cell states in advanced GC patients, highlighting adaptive immune irresponsiveness in GSRCC and a mediator role of CXCL13 in TIME. Our targeted single-cell transcriptomic and proteomic profiling represents a powerful approach for TIME-oriented translational research.
    Journal
    |
    CD8 (cluster of differentiation 8) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CXCL13 expression
    1year
    Single cell analysis reveals tumor evolution and CAR T cell dysfunction associated with tumor resistance (AACR 2023)
    Our findings highlight the complex tumor-T cell interplay as tumor evades CAR T cell killing. Tumor resistance is associated with CAR T cell transition from cytotoxic to dysfunctional phenotypes, the suppression of expanded Treg cells, and the acquisition of resistant features by tumors.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • SSTR (Somatostatin Receptor) • LMNA (Lamin A/C) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • EPCAM (Epithelial cell adhesion molecule) • SSTR2 (Somatostatin Receptor 2) • TNFRSF14 (TNF Receptor Superfamily Member 14) • TNFRSF18 (TNF Receptor Superfamily Member 18) • IFI27 (Interferon Alpha Inducible Protein 27) • DUSP4 (Dual Specificity Phosphatase 4) • SOX4 (SRY-Box Transcription Factor 4)
    |
    CD8 expression • SSTR2 expression • CXCL13 expression • SSTR Expression
    1year
    A novel fatty-acid metabolism-based classification for triple negative breast cancer. (PubMed, Aging (Albany NY))
    This study revealed FAM plays an indispensable role in formation of TNBC heterogeneity and TME diversity. The novel FAM-based classification could provide a promising prognostic predictor and guide more effective immunotherapy strategies for TNBC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • FBP1 (Fructose-Bisphosphatase 1)
    |
    CXCL13 expression
    1year
    Induction of tertiary lymphoid structures in a mouse melanoma model under a combination of CXCL13 and anti-PD-1 antibody (ISID 2023)
    Mice treated with the combination of CXCL13 and anti-PD-1 antibody had significantly more TLSs than mice treated with anti-PD-1 antibody alone (p = 0.0177). The induction of TLS with CXCL13 is expected as a good option to enhance the efficacy of ICI therapy in the treatment of malignant melanoma.
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CXCL13 (Chemokine (C-X-C motif) ligand 13)
    |
    CD20 positive • CXCL13 expression
    over1year
    Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. (PubMed, J Immunother Cancer)
    Our results provide a high-resolution molecular resource and illustrate the importance of major immune lineages as well as their functional substates in understanding the role of the tumor immune microenvironment in response to ICIs.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCR2 (C-C Motif Chemokine Receptor 2)
    |
    CXCL13 expression
    over1year
    Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. (PubMed, Cancer Med)
    We observed that CXCL13 upregulation is correlated to better ICI response in lung adenocarcinoma. Our results support that CXCL13 could be an important chemokine in shaping the immunoactive tumor microenvironment which affects the anti-tumor effect of ICI.
    Journal • Checkpoint inhibition • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • GZMA (Granzyme A) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • PRF1 (Perforin 1)
    |
    CXCL13 expression
    over1year
    Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in epithelial ovarian cancer co-express CXCL13 and associate with improved survival. (PubMed, Front Immunol)
    Analysis of a cohort of ~175 patients with high-grade serous EOC revealed TIM-3-positive Trm were significantly associated with improved patient survival. As CXCL13-positive CD8-positive T cells have been strongly linked to patient response to anti-PD1 immune checkpoint blockade, combinatorial TIM-3 and PD-1 blockade therapy may be of interest for the (re)activation of anti-cancer immunity in EOC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ITGAE (Integrin Subunit Alpha E)
    |
    CD8 expression • CD8 positive • HAVCR2 expression • CXCL13 expression
    over1year
    Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma (ASH 2022)
    We obtained highly multiplexed images for a total of 7,146,042 cells that could be broadly clustered into T cell, macrophage, B cell as well as HRS cells using the phenograph tool. We also identified subsets within the HRS cell cluster, such as GATA3-high HRS cells and CXCR5-high HRS cells. We, then, investigated the difference of TME characteristics according to the disease status.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • GATA3 (GATA binding protein 3)
    |
    CXCL13 expression
    over1year
    Tumor infiltrating CD8/CD103/TIM-3-expressing lymphocytes in Epithelial Ovarian Cancer co-express CXCL13 and associate with improved survival (ESMO-IO 2022)
    Conclusions TIM-3 itself or as surrogate marker for prognostically favorable CXCL13-positive CD8-positive TILs may have prognostic value. As CXCL13-positive CD8-positive T cells have been strongly linked to patient response to anti-PD1 immune checkpoint blockade, combinatorial TIM-3 and PD-1 blockade therapy may be of interest for the (re)activation of anti-cancer immunity in EOC.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • ITGAE (Integrin Subunit Alpha E)
    |
    CD8 expression • CD8 positive • HAVCR2 expression • CXCL13 expression
    over1year
    CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression. (PubMed, J Hematol Oncol)
    Altogether, our findings suggest that bidirectional interactions of MΦ with MM tumor cells result in M2 MΦ polarization, CXCL13 induction, and subsequent OC activation, enhancing their ability to support bone resorption and MM progression. CXCL13 may thus serve as a potential novel target in MM.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • CD163 (CD163 Molecule) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • MRC1 (Mannose Receptor C-Type 1) • TNFSF11 (TNF Superfamily Member 11)
    |
    CXCL13 expression • CXCR4 expression